TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia

NCT04390061 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Pneumonitis, Interstitial
COVID-19

Interventions

DRUG: Tofacitinib
DRUG: Hydroxychloroquine

Sponsor

Università Politecnica delle Marche

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]